RANI 1Q24 Results

RANI Stock  USD 2.02  0.03  1.51%   
Under 59% of all Rani Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that some traders are interested. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
  
By John Vandermosten, CFA NASDAQRANI READ THE FULL RANI RESEARCH REPORT Rani Therapeutics Holdings, Inc. reported first quarter 2024 results on May 6th, 2024. However, there has been little public interaction since full year results were reported seven weeks earlier. In the interim, Rani has been focused on its negotiations with Celltrion and possibly others for further development

Read at finance.yahoo.com
Yahoo News
  

Rani Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Rani Therapeutics Fundamental Analysis

We analyze Rani Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Rani Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Rani Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rani Therapeutics stock to make a market-neutral strategy. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with similar companies.

Peers

Rani Therapeutics Related Equities

CABACabaletta Bio   26.91   
0%
100.0%
SRZNSurrozen   19.37   
0%
71.0%
GLUEMonte Rosa   13.72   
0%
50.0%
LYRALyra Therapeutics   10.53   
0%
39.0%
MNPRMonopar Therapeutics   8.84   
0%
32.0%
TNYATenaya Therapeutics   8.51   
0%
31.0%
VINCVincerx Pharma   7.69   
0%
28.0%
BMEABiomea Fusion   3.13   
0%
11.0%
VCNXVaccinex   2.44   
0%
9.0%
TRVITrevi Therapeutics   2.13   
0%
7.0%
PMVPPmv Pharmaceuticals   1.25   
0%
4.0%
MOLNMolecular Partners   0.17   
1.0%
0%
TARAProtara Therapeutics   0.99   
3.0%
0%
ALXOAlx Oncology   1.99   
7.0%
0%
TYRATyra Biosciences   2.00   
7.0%
0%
PHVSPharvaris   2.06   
7.0%
0%
EYPTEyepoint Pharmaceuticals   2.21   
8.0%
0%
CRVSCorvus Pharmaceuticals   3.50   
13.0%
0%
VIRXViracta Therapeutics   6.67   
24.0%
0%

Complementary Tools for Rani Stock analysis

When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon